People In Brief: NSF, Xango, GNC, NCCAM, MHRA

FDA’s Williams moves to NSF; Xango founders take international posts; Fortino returns to GNC as VP; Hamilton moves up at Hyland’s; Shurtleff moves to NCCAM; more People In Brief.

Bradford Williams, a former manager in FDA’s good manufacturing practices program for dietary supplements, starts as technical manager of NSF International’s Supplement GMP Facility Registration Program. Williams worked at FDA for more than 30 years, including eight in the agency’s Division of Dietary Supplement Programs, where he assisted in developing supplement GMP requirements and training programs for FDA investigators and managed the review of more than 350 facility investigations and enforcement actions. “Since Brad has worked with the FDA’s GMP program since its inception, his expertise will assist NSF in continuing to align its GMP program with FDA regulations,” said Ed Wyszumiala, general manager of Ann Arbor, Mich.-based NSF’s supplement programs, in a July 22 release.

Multilevel dietary supplement marketer Xango LLC on July 3 appoints two company founders to new roles: Joe Morton as president...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

More from Geography

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.